Physician profile
Andrew Mackelprang
NPI 1891147658
$2,010.11
in general payments reported to CMS, 2019-2025
17 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.73 · 2020: $152 · 2021: $140 · 2022: $288 · 2023: $396 · 2024: $574 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Entertainment: $150 · Education: $36.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.12 |
| Entertainment | $150.09 |
| Education | $36.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $599.23 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $267.46 | 2022-2025 | Xiidra, Miebo, Infuse |
| Oyster Point Pharma, INC. | $199.69 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Coopervision INC. | $182.97 | 2020-2024 | Clariti Contact Lens, Biofinity Contact Lens |
| Dompe US, INC. | $151.61 | 2024 | Oxervate |
| Optos, INC. | $150.09 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $94.02 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $90.77 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $87.28 | 2020-2022 | |
| Glaukos Corporation | $53.82 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.04 | 2021 | |
| Biotissue Holdings INC. | $22.35 | 2022 | |
| Abbvie INC. | $20.40 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.17 | 2025 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.68 | 2022 | |
| Sight Sciences, INC. | $14.13 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mackelprang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.